BACKGROUND Pantoprazole is a selective inhibitor of the gastric H+/K+-ATPase with a low potential to interact with the cytochrome P450 enzyme system. Since pantoprazole is metabolized in the liver to metabolites which are mainly cleared by the renal route, it was the aim of this study to investigate its pharmacokinetics in patients with end-stage renal failure undergoing regular haemodialysis. ...

BACKGROUND Survival statistics for daily haemodialysis are lacking as most centres providing this have treated only a small number of patients for short observation times. We pooled our 23-year, 1006-patient-year, five-centre experience of 415 patients treated by short daily haemodialysis. METHODS One hundred and fifty patients were treated in-centre, most because of medical complications and...

The assessment of the level of hydration in the intravascular fluid compartment in acute renal failure (ARF) and multiple organ failure (MOF) is of an utmost importance. However, the data on monitoring of blood volume in these diseases and especially during haemodialysis treatment are lacking. This article summarizing the experience of monitoring of blood volume in chronic haemodialysis suggest...

Edoxaban is an oral, direct, once-daily, factor Xa inhibitor developed for stroke prevention in patients with atrial fibrillation and for the treatment and secondary prevention of recurrent thromboembolism in patients with acute symptomatic venous thromboembolism. Among elderly patients who require anticoagulation therapies, some may have end-stage renal disease (ESRD). This open-label, phase 1...

Anticoagulation is an important component of haemodialysis treatment in all settings. The therapeutic options available for anticoagulation of home haemodialysis are similar to those for haemodialysis in other settings. However, dialysis sessions with a wide range of treatment durations are undertaken at home, which can require different approaches to anticoagulation. Conference delegates were ...

BACKGROUND Evidence points to activation of pro-inflammatory and pro-thrombotic stimuli during the haemodialysis process in end-stage renal disease (ESRD) with potential to predispose to cardiovascular events. Diabetes is associated with a higher incidence of cardiovascular disease in haemodialysis patients. We tested the hypothesis that a range of mediators and markers that modulate cardiovasc...

Acquired polycystic kidney disease occurs as one of the sequelae of chronic haemodialysis. Spontaneous perirenal haemorrhage of acquired polycystic kidney disease in a patient on chronic haemodialysis is an uncommon clinical entity [1–4], and bilateral perirenal haemorrhage in these patients is rare [5]. This report describes one case of bilateral perirenal haemorrhage in a haemodialysis patien...

Acute metabolic decompensation in maple syrup urine disease can occur during intercurrent illness and is a medical emergency. A handful of reports in the medical literature describe the use of peritoneal dialysis and haemodialysis as therapeutic inventions. We report the only patient from our centre to have haemodialysis performed in this setting. Combined with dietary BCAA restriction and calo...

AIM Atrial fibrillation (AF) is common in haemodialysis patients, but the risks and benefits of anticoagulation in this group are not well characterized. We investigated the prevalence of AF, its associated risk factors, and the incidence of stroke and haemorrhage in a cohort of haemodialysis patients. METHODS We retrospectively reviewed 155 patients undergoing maintenance haemodialysis on 1 ...

OBJECTIVE Interatrial block (IAB) connotes a P wave duration ≥ 110 msec on electrocardiography (ECG). P-terminal force corresponds to a biphasic P wave with its terminal negative phase ≥ 40 msec x mm in V1 derivation on ECG. IAB and P-terminal force are closely related parameters and they are accepted as predictors for left atrial dysfunction, left atrial dilatation, atrial fibrillation and str...